First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients-Reference-Cited by-同舟云学术

First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients

Published:2020-11 Issue:6 Volume:21 Page:e572-e582
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Lee Youngjoo,Kim Hyae Young,Nam Byung-Ho,Lee Geon Kook,Kim Heung Tae,Han Ji-Youn,An Hye Jin,Lee Jin Soo

Funder

AstraZeneca Korea

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer;Mendelsohn;J Clin Oncol,2003

2. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer;Sridhar;Lancet Oncol,2003

3. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected];Fukuoka;J Clin Oncol,2003

4. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial;Kris;JAMA,2003

5. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors;Future Oncology;2024-09-04

2. Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment;Current Drug Targets;2024-05